Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1B2 | O75343 | 11/20 | 0.49 |
| ▸ | GUCY1A2 | P33402 | 11/20 | 0.49 |
| ▸ | GUCY1A1 | Q02108 | 11/20 | 0.49 |
| ▸ | GUCY1B1 | Q02153 | 11/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15664743 | 0.91 | GUCY1B2 (0.48) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1SMN1; SMN2 | |
| SCHEMBL15705453 | 0.89 | GUCY1B2 (0.51) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| Hydrochloric Acid SCHEMBL15665213 | 0.88 | GUCY1B2 (0.51) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL15663607 | 0.88 | GUCY1B2 (0.49) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1SMN1; SMN2 | |
| SCHEMBL15664810 | 0.86 | GUCY1B2 (0.64) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1SMN1; SMN2 | |
| SCHEMBL15671363 | 0.84 | GUCY1B2 (0.46) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1SMN1; SMN2 | |
| SCHEMBL15663756 | 0.83 | SMN1; SMN2 (0.45) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1SMN1; SMN2 | |
| SCHEMBL15663587 | 0.82 | MAPK1 (0.50) | SMN1; SMN2ALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL16403153 | 0.82 | GUCY1B2 (0.46) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| Trifluoroacetic Acid SCHEMBL15665954 | 0.81 | GUCY1B2 (0.63) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776997-B2 | 3-aryl-substituted imidazo[1,2-A]pyridines and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-03 | — | — | US | disclosed |
| US-9776997-B2 | 3-aryl-substituted imidazo[1,2-A]pyridines and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-03 | — | — | US | disclosed |
| US-9776997-B2 | 3-aryl-substituted imidazo[1,2-A]pyridines and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-03 | — | — | US | disclosed |
| US-9771360-B2 | Cyano-substituted imidazo[1,2-A]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-26 | — | — | US | disclosed |
| US-9771360-B2 | Cyano-substituted imidazo[1,2-A]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-26 | — | — | US | disclosed |
| US-9771360-B2 | Cyano-substituted imidazo[1,2-A]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-26 | — | — | US | disclosed |
| US-20170217954-A1 | CYANO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-03 | — | — | US | disclosed |
| US-20170217954-A1 | CYANO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-03 | — | — | US | disclosed |
| US-20170217954-A1 | CYANO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-03 | — | — | US | disclosed |
| EP-2914596-B1 | HYDROXY SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE CARBOXAMIDES AND THEIR USE AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE | Bayer Pharma AG (DE) | 2017-06-21 | — | — | EP | disclosed |
| WO-2015140199-A1 | CYANO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-09-24 | — | — | WO | disclosed |
| EP-2914596-A1 | HYDROXY-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE AS SOLUBLE GUANYLATE CYCLASE STIMULANTS | Bayer Pharma Aktiengesellschaft (DE) | 2015-09-09 | — | — | EP | disclosed |
| US-8946215-B2 | Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8946215-B2 | Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8946215-B2 | Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-02-03 | — | — | US | disclosed |
| WO-2014195333-A1 | 3-ARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-11 | — | — | WO | disclosed |
| US-20140128386-A1 | Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| US-20140128386-A1 | Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| US-20140128386-A1 | Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| WO-2014068104-A1 | HYDROXY-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE AS SOLUBLE GUANYLATE CYCLASE STIMULANTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217954-A1 | CYANO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE | AADAC, TNNI3, PCCA | GUCY1B2 454/4885GUCY1A2 264/4885GUCY1A1 477/4885 |
| US-20140128386-A1 | Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use | AADAC, TNNI3, PAH | GUCY1B2 793/4885GUCY1A2 719/4885GUCY1A1 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.